AlloVir
ALVR

Ticker changed

ALVR changed its ticker symbol to KLRS

See KLRS stock details

About: AlloVir Inc is a biopharmaceutical company. The company focuses on developing allogeneic T-cell therapies to combat viral diseases. Their proprietary virus-specific T cell VST therapy platform enables the creation of off-the-shelf VSTs, therapy platform allows AlloVir to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. This included: (1) posoleucel (ALVR105), an investigational off-the-shelf multi-virus-specific T cell therapy. (2) ALVR106, an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by four respiratory viruses. (3) ALVR107, an allogeneic, off-the-shelf VST therapy candidate designed to target hepatitis B (HBV).

Employees: 6

Healthcare Biological Products, Except Diagnostic Substances

Financial journalist opinion

Kalaris Announces Closing of Merger with AlloVir

Kalaris is focused on developing TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina

Kalaris Announces Closing of Merger with AlloVir

Kalaris and AlloVir Announce Stockholder Approval of Merger

Combined company expected to trade on Nasdaq under “KLRS” after closing Combined company expected to trade on Nasdaq under “KLRS” after closing

Kalaris and AlloVir Announce Stockholder Approval of Merger

ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc. - ALVR

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AlloVir, Inc. (the “Company”) (NasdaqCM: ALVR) and Kalaris Therapeutics. Pursuant to the terms of the agreement, upon completion of the Merger, pre-Merger AlloVir stockholders are expected to own approximately 25.05% of the combined company. KSF is seeking to determine whether the merger and the process that.

ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc. - ALVR

ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc. - ALVR

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AlloVir, Inc. (the “Company”) (NasdaqCM: ALVR) and Kalaris Therapeutics. Pursuant to the terms of the agreement, upon completion of the Merger, pre-Merger AlloVir stockholders are expected to own approximately 25.05% of the combined company. KSF is seeking to determine whether the merger and the process that.

ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc. - ALVR

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EMKR and ALVR on Behalf of Shareholders

NEW YORK, Nov. 09, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EMKR and ALVR on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EMKR and ALVR on Behalf of Shareholders

NEW YORK , Nov. 8, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EMCORE Corporation (NASDAQ: EMKR)'s sale to Velocity One for $3.10 per share in cash. If you are an EMCORE shareholder, click here to learn more about your legal rights and options.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EMKR and ALVR on Behalf of Shareholders

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of AlloVir, Inc. – ALVR

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating AlloVir , Inc. (NASDAQ: ALVR ), relating to its proposed merger with Kalaris Therapeutics. Under the terms of the agreement, AlloVir will acquire 100% of the outstanding equity interest of Kalaris. Upon completion of the Merger, pre-Merger AlloVir stockholders are expected to own approximately 25.05% of the combined company and pre-Merger Kalaris stockholders are expected to own approximately 74.95% of the combined company.

STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of AlloVir, Inc. – ALVR

Shareholder Alert: Ademi LLP Investigates Whether AlloVir, Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating AlloVir (Nasdaq: ALVR) for possible breaches of fiduciary duty and other violations of law in its transaction with Kalaris. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, stockholders of AlloVir will own only approximately 25.05% of the combined company and pre-Merger Kalaris stockh.

Shareholder Alert: Ademi LLP Investigates Whether AlloVir, Inc. Is Obtaining a Fair Price for Its Public Shareholders

ALVR Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of AlloVir, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of AlloVir, Inc. (NASDAQ: ALVR) and Kalaris Therapeutics is fair to AlloVir shareholders. Halper Sadeh encourages AlloVir shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether AlloVir and its board violated the federa.

ALVR Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of AlloVir, Inc. Is Fair to Shareholders

AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina

Kalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a novel, differentiated and potentially transformative therapy for patients with neovascular and exudative retinal diseases

AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina

See News Rankings

Charts implemented using Lightweight Charts™